Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

AVEO Oncology and Biodesix to discontinue CyFi-2 study of ficlatuzumab in AML in response to public health crisis

pharmaceutical-business-reviewApril 01, 2020

Tag: Aveo Oncology , Biodesix , CyFi-2 , ficlatuzumab

PharmaSources Customer Service